Rui He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rui He has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Cailan Li
Department of Pharmacology, Zunyi Medical University, Zhuhai Campus, Zhuhai 519041, PR China
1 shared publication - Qiang Lu
Department of Pharmaceutical Sciences, Zunyi Medical University, Zhuhai Campus, Zhuhai 519041, China
1 shared publication - Ruoting Zhan
Research Center of Chinese Herbal Resource Science and Engineering, Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication - Weiwen Chen
Department of Endocrinology Medical College of Wisconsin Milwaukee Wisconsin USA
1 shared publication - Zhongfeng Shi
New Drug Research Center, Guangdong Pharmaceutical University, No. 280 Waihuan East Road, Panyu District, Guangzhou 510006, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 6806943
Clinical Efficacy of Jinshuibao Capsules Combined with Angiotensin Receptor Blockers in Patients with Early Diabetic Nephropathy: A Meta‐Analysis of Randomized Controlled Trials
Background. Jinshuibao capsules (JSB) have been widely used to treat early diabetic nephropathy (DN), but the specific effects are still inconsistent. A meta‐analysis of randomized controlled trials (RCTs) was conducted to evaluate the clinical efficacy of JSB for early DN. Methods. Four international databases and four Chinese databases were searched from publication dates to March 1, 2018. The RCTs reporting the results of JSB’s specific effects were included, and comparisons were between JSB combined with Angiotensin Receptor Blockers (ARBs) as experimental intervention and ARBs as the control. Included studies’ quality was evaluated and the extracted data were analyzed with RevMan 5.3 software. Results. Twenty‐six RCTs including 2198 early DN participants were adopted in the meta‐analysis. The results showed that, compared with the ARBs alone, JSB could remarkably improve the ORR (OR = 3.84; 95% CI: 2.37~6.24; P < 0.00001) and decrease 24 h UTP (MD = −93.32; 95% CI: −128.60 ~−58.04; P < 0.00001), UAER (MD = −24.02; 95% CI: −30.93 ~−17.11; P < 0.00001), BUN (MD = −0.26; 95%: −0.44 ~−0.08; P = 0.005), Scr (MD = −9.07; 95% CI: −14.26 ~−3.88; P = 0.0006), ACR (MD = −17.55; 95% CI: −22.81 ~−12.29; P < 0.00001), Cys‐C (MD = −0.60; 95% CI: −0.88 ~−0.32; P < 0.00001), SBP (MD = −3.08; 95% CI: −4.65 ~−1.52; P = 0.0001), DBP (MD = −2.09; 95% CI: −4.00 ~−0.19; P = 0.03), and TG (MD = −0.36; 95% CI: −0.50 ~−0.21; P < 0.00001). However, it showed no significant differences in TC (MD = −0.32; 95% CI: −0.69~0.04; P = 0.08), FBG (MD = 0.04; 95% CI: −0.39~0.47; P = 0.87), HbA1c (MD = −0.26; 95% CI: −0.59~0.06; P = 0.11), and β2‐MG (MD = −15.61; 95% CI: −32.95~1.73; P = 0.08). Conclusions. This study indicates that JSB is an effective accessory therapeutic medicine for patients with early DN. It contributes to decreasing blood pressure and the content of triglyceride and improving the renal function of early DN patients. However, there is still a need to further verify the auxiliary therapeutic effect of JSB with more strictly designed RCTs with large sample and multiple centers in the future.
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 6806943
Open AccessClinical Efficacy of Jinshuibao Capsules Combined with Angiotensin Receptor Blockers in Patients with Early Diabetic Nephropathy: A Meta‐Analysis of Randomized Controlled Trials
Background. Jinshuibao capsules (JSB) have been widely used to treat early diabetic nephropathy (DN), but the specific effects are still inconsistent. A meta‐analysis of randomized controlled trials (RCTs) was conducted to evaluate the clinical efficacy of JSB for early DN. Methods. Four international databases and four Chinese databases were searched from publication dates to March 1, 2018. The RCTs reporting the results of JSB’s specific effects were included, and comparisons were between JSB combined with Angiotensin Receptor Blockers (ARBs) as experimental intervention and ARBs as the control. Included studies’ quality was evaluated and the extracted data were analyzed with RevMan 5.3 software. Results. Twenty‐six RCTs including 2198 early DN participants were adopted in the meta‐analysis. The results showed that, compared with the ARBs alone, JSB could remarkably improve the ORR (OR = 3.84; 95% CI: 2.37~6.24; P < 0.00001) and decrease 24 h UTP (MD = −93.32; 95% CI: −128.60 ~−58.04; P < 0.00001), UAER (MD = −24.02; 95% CI: −30.93 ~−17.11; P < 0.00001), BUN (MD = −0.26; 95%: −0.44 ~−0.08; P = 0.005), Scr (MD = −9.07; 95% CI: −14.26 ~−3.88; P = 0.0006), ACR (MD = −17.55; 95% CI: −22.81 ~−12.29; P < 0.00001), Cys‐C (MD = −0.60; 95% CI: −0.88 ~−0.32; P < 0.00001), SBP (MD = −3.08; 95% CI: −4.65 ~−1.52; P = 0.0001), DBP (MD = −2.09; 95% CI: −4.00 ~−0.19; P = 0.03), and TG (MD = −0.36; 95% CI: −0.50 ~−0.21; P < 0.00001). However, it showed no significant differences in TC (MD = −0.32; 95% CI: −0.69~0.04; P = 0.08), FBG (MD = 0.04; 95% CI: −0.39~0.47; P = 0.87), HbA1c (MD = −0.26; 95% CI: −0.59~0.06; P = 0.11), and β2‐MG (MD = −15.61; 95% CI: −32.95~1.73; P = 0.08). Conclusions. This study indicates that JSB is an effective accessory therapeutic medicine for patients with early DN. It contributes to decreasing blood pressure and the content of triglyceride and improving the renal function of early DN patients. However, there is still a need to further verify the auxiliary therapeutic effect of JSB with more strictly designed RCTs with large sample and multiple centers in the future.